Form 4: Sagimet Biosciences Executive Chairman Sells Shares Under 10b5-1 Trading Plan

George Kemble, Executive Chairman of Sagimet Biosciences, sold 23,625 shares of Series A Common Stock at an average price of $3.1674 per share under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 23, 2024, George Kemble, the Executive Chairman of Sagimet Biosciences Inc. (SGMT), sold 23,625 shares of Series A Common Stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on February 27, 2024.
• The weighted average price for the shares sold was $3.1674.
• The prices ranged from $3.07 to $3.26 per share.
• Following the transaction, Kemble directly owns 118,693 shares of Sagimet Biosciences Inc.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sale of shares by an executive is neither inherently positive nor negative, especially when conducted under a pre-arranged trading plan.

Industry Context

Sales by company executives are a normal part of corporate governance. The fact that the sale was executed under a 10b5-1 trading plan suggests that the sale was pre-planned and not based on any inside information.

Stakeholder Impact

• The sale of shares by the Executive Chairman could have a minor negative impact on shareholder sentiment, but the impact is likely to be minimal given the pre-planned nature of the transaction.

Key Dates